<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117401</url>
  </required_header>
  <id_info>
    <org_study_id>20121101</org_study_id>
    <nct_id>NCT02117401</nct_id>
  </id_info>
  <brief_title>A Prospective, Multi-center, Randomized Controlled Study of Muscle Relaxation Effect and Safety of Mivacurium Chloride in Pediatric Surgery Patients</brief_title>
  <official_title>A Prospective, Multi-center, Randomized Controlled Study of Neuromuscular Blocking Effect and Safety of Mivacurium Chloride in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Nhwa Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Nhwa Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect and safety of mivacurium chloride in pediatric patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intubation score</measure>
    <time_frame>1 minute within intubation</time_frame>
    <description>Krieg Tracheal Intubation Score
Score ： 1 2 3 4
Laryngoscopy ： Easy Fair Difficult Impossible
Vocal cords： Open Moving Closing Closed
Coughing： None Diaphragm Mild Severe
A total score of 3-4 = excellent, 5-7 = good, 8-10 = poor, 11-12 = bad.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>muscle relaxation effect</measure>
    <time_frame>from baseline to no more than 120 minutes after intubation</time_frame>
    <description>Recording T1 and TOFR（Train of four ratio) before/after the induction of anesthesia -Onset time of Mivacurium：time from end of injection until occurrence of maxi- mum block
Duration of clinical relaxation：time to recovery of Tl(the first response in the TOF) to 25%
Recovery index：Time interval during with T1 recovered from 25%</description>
  </primary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">1152</enrollment>
  <condition>Efficacy and Safety of Mivacurium Chloride for Pediatric Patients</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 20 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 40 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mivacurium chloride</intervention_name>
    <description>intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.</description>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_label>group 5</arm_group_label>
    <arm_group_label>group 6</arm_group_label>
    <arm_group_label>group 7</arm_group_label>
    <arm_group_label>group 8</arm_group_label>
    <arm_group_label>group 9</arm_group_label>
    <arm_group_label>group 10</arm_group_label>
    <arm_group_label>group 11</arm_group_label>
    <arm_group_label>group 12</arm_group_label>
    <arm_group_label>group 13</arm_group_label>
    <arm_group_label>group 14</arm_group_label>
    <arm_group_label>group 15</arm_group_label>
    <arm_group_label>group 16</arm_group_label>
    <other_name>mivacron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children
Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg</description>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_label>group 5</arm_group_label>
    <arm_group_label>group 6</arm_group_label>
    <arm_group_label>group 7</arm_group_label>
    <arm_group_label>group 8</arm_group_label>
    <arm_group_label>group 9</arm_group_label>
    <arm_group_label>group 10</arm_group_label>
    <arm_group_label>group 11</arm_group_label>
    <arm_group_label>group 12</arm_group_label>
    <arm_group_label>group 13</arm_group_label>
    <arm_group_label>group 14</arm_group_label>
    <arm_group_label>group 15</arm_group_label>
    <arm_group_label>group 16</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketamine</intervention_name>
    <description>mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children
Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg</description>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_label>group 5</arm_group_label>
    <arm_group_label>group 6</arm_group_label>
    <arm_group_label>group 7</arm_group_label>
    <arm_group_label>group 8</arm_group_label>
    <arm_group_label>group 9</arm_group_label>
    <arm_group_label>group 10</arm_group_label>
    <arm_group_label>group 11</arm_group_label>
    <arm_group_label>group 12</arm_group_label>
    <arm_group_label>group 13</arm_group_label>
    <arm_group_label>group 14</arm_group_label>
    <arm_group_label>group 15</arm_group_label>
    <arm_group_label>group 16</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min</description>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_label>group 5</arm_group_label>
    <arm_group_label>group 6</arm_group_label>
    <arm_group_label>group 7</arm_group_label>
    <arm_group_label>group 8</arm_group_label>
    <arm_group_label>group 9</arm_group_label>
    <arm_group_label>group 10</arm_group_label>
    <arm_group_label>group 11</arm_group_label>
    <arm_group_label>group 12</arm_group_label>
    <arm_group_label>group 13</arm_group_label>
    <arm_group_label>group 14</arm_group_label>
    <arm_group_label>group 15</arm_group_label>
    <arm_group_label>group 16</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min</description>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_label>group 5</arm_group_label>
    <arm_group_label>group 6</arm_group_label>
    <arm_group_label>group 7</arm_group_label>
    <arm_group_label>group 8</arm_group_label>
    <arm_group_label>group 9</arm_group_label>
    <arm_group_label>group 10</arm_group_label>
    <arm_group_label>group 11</arm_group_label>
    <arm_group_label>group 12</arm_group_label>
    <arm_group_label>group 13</arm_group_label>
    <arm_group_label>group 14</arm_group_label>
    <arm_group_label>group 15</arm_group_label>
    <arm_group_label>group 16</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The parent/guardian must sign a parental permission consent document

          -  American Society of Anesthesiologists (ASA) physical status class 1-3

          -  Elective surgery patients with tracheal intubation, and the operation duration is
             expected to be longer than 30 min but no longer than 120 min(cleft lip and palate,
             orthopedic, bilateral hernia, bilateral cryptorchidism, hypospadias crack, and other
             ear, nose and throat surgery, etc)

          -  Age between 2 months to 14 Years

        Exclusion Criteria:

          -  BMI&lt;18kg/m2 or BMI&gt;31kg/m2

          -  Patients with serious respiratory, cardiovascular disease, and liver and kidney
             dysfunction[AST（glutamic oxalacetic transaminase）,ALT(glutamic-pyruvic
             transaminase)&gt;1.5 Normal;BUN(blood urea nitrogen)&gt;Normal)]

          -  Patients with asthma or airway hyperresponsiveness, neuromuscular patients disease or
             cachexia

          -  Preoperative hemoglobin less than 10g/L

          -  Hypoproteinemia TP（total protein) &lt;45g/L

          -  Diabetic patients

          -  Patients with difficulty airway

          -  Patients with Known or suspected atypical plasma cholinesterase gene homozygous

          -  Burn patients

          -  Patients with serious acid-base imbalances, or severe electrolyte imbalance

          -  Patients with neuromuscular relaxants in a week

          -  Patients prohibited with muscle relaxants, or allergy to any component of mivacurium

          -  Patients participated in any drug clinical trial with 30 days before the start of the
             study

          -  Other situations not suitable for inclusion

          -  Blood loss more than 10 ml/kg in surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2014</study_first_submitted>
  <study_first_submitted_qc>April 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>July 14, 2014</last_update_submitted>
  <last_update_submitted_qc>July 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Mivacurium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

